Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...